A look at the late-stage vaccine pipeline

In 2009, the world market for preventive vaccines totaled $22.1 billion, up from $19.0 billion in 2008, and is expected to grow at a compound annual rate of 9.7 percent to $35 billion in 2014. That's according to Kalorama Information, which has broken out a list of notable vaccines in late-stage development. Merck, GlaxoSmithKline, Sanofi Pasteur, Pfizer and Novartis combined control 83.9 percent of the world market, with GSK being the biggest vaccine seller.

As of mid-2010, Kalorama estimates there are more than 200 pediatric vaccines and many more adult preventative vaccines in development, although most are at the earliest stages of the testing process.

Source: Kalorama Information

Pediatric vaccine sales outstrip adult vaccine sales and are expected to increase at a faster rate than adult vaccines. Combination and pneumonoccal vaccines are expected to lead the growth. While adult vaccines currently make up 47.8 percent of the market, that share will likely decrease by 44.6 percent in 2014. Influenza vaccines will likely be the fastest growing segment of the adult vaccine market over the next five years.

Source: Kalorama Information

Kalorama has selected important late-stage vaccines that address vaccine preventable conditions (developmental products addressing not yet-preventable diseases will be covered in a separate report). Sanofi Pasteur, the vaccine arm of Sanofi-Aventis, leads the way with five pediatric and adult vaccines in late stage development. All vaccines listed on this chart are in Phase III trials or have already been submitted to U.S. or EU regulators for approval.

Phase III vaccines in development